ProQR (PRQR): Reiterating Outperform Ahead of NACFC - Leerink

October 14, 2016 10:17 AM EDT
Get Alerts PRQR Hot Sheet
Price: $4.40 --0%

Rating Summary:
    4 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 31 | New: 34
Trade PRQR Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Leerink Partners analyst, Joseph Schwartz, reiterated his Outperform on ProQR Therapeutics N.V. (NASDAQ: PRQR) heading into the North American Cystic Fibrosis Conference (NACFC; Oct 27-29).

The analyst is expecting the first set of human data for QR-010 in cystic fibrosis (CF) patients. Although still early, QR-010 has shown promise in preclinical studies that could translate into functional efficacy in humans. The analyst believes that data from the nasal potential difference (NPD) and Phase 1b single-ascending dose (SAD) studies will be limited in scale and scope but may provide the first indication that ProQR’s innovative antisense oligonucleotide (AON) technology has the potential to repair RNA implicated in various diseases.

No change to the $14 price target.

For an analyst ratings summary and ratings history on ProQR Therapeutics N.V. click here. For more ratings news on ProQR Therapeutics N.V. click here.

Shares of ProQR Therapeutics N.V. closed at $6.42 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment